Key Takeaways
- Island Pharmaceuticals has expanded its agreement with USAMRIID and Geneva Foundation to advance the Galidesivir program for Marburg virus disease.
- A dose optimisation study is set to start next quarter, with results expected by late 2026.
- Galidesivir has shown promising survival rates in animal studies and is positioned for potential FDA approval under the Animal Rule pathway.
Expansion of Research Agreement
Island Pharmaceuticals (ASX: ILA) is progressing in its fight against Marburg virus disease through an expanded Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Geneva Foundation. This amended agreement outlines plans for a dose optimisation study, focusing on the Angola strain of the virus. The study is set to commence next quarter, with topline results anticipated in the latter half of 2026.
USAMRIID’s Biosafety Level 4 infrastructure will be utilized during this study, which aims to determine the minimally effective dose of Galidesivir. This facility is uniquely equipped among U.S. Department of War laboratories for high-risk pathogen research.
Advancements in Animal Rule Pathway
The expanded agreement also enhances Island’s two-stage Animal Rule development program and strengthens ties with U.S. biodefense agencies. Previous non-human primate trials with Galidesivir showed a survival rate of 94% against the Marburg Musoke strain, in stark contrast to a 0% survival rate in placebo groups.
The upcoming study will focus on the primary endpoint of survival rates 28 days post-exposure, while also evaluating clinical signs and pharmacokinetic parameters. Different dosing regimens will be tested, with treatment starting 24 or 48 hours after virus exposure.
Operational Planning and Strategic Milestones
Island is finalizing operational strategies and study preparations with USAMRIID and Geneva, with the dosing phase expected to last around 30 days. Successful outcomes from this study could pave the way for a pivotal confirmatory efficacy study, essential for potential FDA approval.
Dr. David Foster, CEO of Island Pharmaceuticals, remarked that the expanded agreement represents a significant achievement for the company. He emphasized the importance of access to USAMRIID’s facilities in mitigating risks inherent to the drug development process, especially given the rising global concerns over Marburg and Ebola viruses.
Galidesivir is recognized as one of the few broad-spectrum antiviral candidates capable of addressing multiple high-priority viral threats. Island is also advancing its dual development strategy encompassing Galidesivir and ISLA-101, aimed at dengue fever and other mosquito-borne diseases.
To provide further insights, Island will host an investor webinar on Friday discussing the expanded CRADA and related biodefense initiatives, especially concerning threats posed by Ebola and the Sudan virus.
The content above is a summary. For more details, see the source article.